Emcure Pharmaceuticals delivered exceptional fourth quarter results with consolidated net profit rising 24% to ₹243.74 crore compared to ₹197.24 crore in the corresponding quarter last fiscal. Consolidated revenue from operations reached ₹2,469.7 crore versus ₹2,116.25 crore year-on-year, demonstrating robust growth momentum. As per the company's regulatory filing, total expenses increased to ₹2,142.82 crore from ₹1,849.7 crore in the previous year quarter. For the full fiscal year FY26, the company achieved consolidated net profit of ₹941.27 crore compared to ₹707.47 crore in FY25, with revenue from operations growing 16.6% to ₹9,203.54 crore from ₹7,896 crore in the previous year.
The company's international business emerged as the primary growth driver, with sales reaching ₹1,493 crore, up 25.7% year-on-year, supported by strong performance across markets and new product launches. According to the company's statement, this robust growth was driven by base business ramp-up and new product launches. In contrast, domestic business sales were ₹977 crore, up 5.2% year-on-year, with softer performance attributed to the Zuventus portfolio and team reorganisation. The domestic market accounts for 44% of total revenue, with emerging markets and Europe each contributing 20% and Canada making up the remaining 16%.
Emcure is positioning biosimilars as a key growth driver, with managing director Satish Mehta telling Mint that the company will increase R&D spending and portfolio contribution toward biosimilars over the next three to five years. The Pune-headquartered company currently has six biosimilars in the market launched through its subsidiary Gennova Biopharmaceuticals, which it has developed in-house. However, executive director Samit Mehta revealed that the company will now scout for partners for products not in its pipeline for commercialisation in India and emerging markets. As per the latest developments, the company's R&D pipeline in complex injectables and biosimilars remains a key driver of future value.
The company's board has approved the re-appointment of Satish Mehta as Managing Director for a further period of five years commencing from April 1, 2027, subject to shareholders' approval. Additionally, the board of directors has recommended a final dividend of ₹3.6 per fully paid up ordinary share of ₹10 each for the year ended March 2026, subject to approval by the shareholders. Commenting on the performance, CEO and MD Satish Mehta highlighted that "In FY26, the first year of our five-year strategic plan, Emcure delivered strong financial performance with over $1 billion in revenue and 16.6% growth," emphasizing the company's commitment to delivering sustainable, above-industry growth and consistent margin expansion.
